Puricase, First New Drug Treatment Approach For Gout In 40 Years, Could Potentially Revolutionise Treatment For Some
The first new class of drug to emerge in 40 years for treating chronic gout has the potential to radically alter the outlook for thousands of patients unable to benefit from currently available therapies, says the drug’s developer Savient Pharmaceuticals Inc. who presented Phase II data at this year’s annual meeting of the European rheumatology community, EULAR.
